Categories: BioTechInformationPersonalPlatformResearchUniversity
Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit www.shinobitx.com.
Investors 4
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.08.2024 | Grant | $59M | - |
| 26.12.2023 | Series A | $51M | - |
Mentions in press and media 7
| Date | Title | Description |
| 06.08.2024 | Shinobi Therapeutics Secures $59M Grant; Extends Series A Round | Shinobi Therapeutics, a San Francisco, CA-based biotechnology company developing a new class of immune evasive iPS cell therapies, received a $59M grant.
The non-dilutive grant funding, provided by the Japanese Agency for Medical Research a... |
| 30.05.2024 | Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology | Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
Thu, May 30, 2024 12:00 CET Report this content
Södertälje, Sweden, & San Francisco, USA and Kyoto, Japan, 30 May 2... |
| 26.12.2023 | Shinobi announced their $51M Series A funding | Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell therapies, announced their launch and $51M Series A funding.
Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrate... |
| 12.12.2023 | Shinobi Therapeutics, Inc. Shinobi Therapeutics completes $51 million Series A to develop a low-immunogenic iPS cell-derived T cell therapy platform | Shinobi Therapeutics Co., Ltd.
Shinobi Therapeutics completes $51 million Series A to develop low-immunogenic iPS cell-derived T cell therapy platform
Technology introduced from Kyoto University and University of California, San Francisco t... |
| 12.12.2023 | Shinobi Therapeutics Raises $51M in Series A Funding | Shinobi Therapeutics, a San Francisco, CA- and Kyoto, Japan-based biotechnology company developing a new class of immune evasive iPS-T cell therapies, closed a $51m Series A financing.
The round was led by EQT Life Sciences, F-Prime Capital... |
| 12.12.2023 | Exclusive: Shinobi raises $51M to take on cell therapy challenges with ex-Wugen CEO at helm, Carl June in support | - |
| - | Shinobi Therapeutics | “Shinobi Therapeutics” |
Reviews 0
